Oxelumab is a monoclonal antibody designed to target TNFSF4, also known as OX40L or CD252, a protein involved in immune system regulation. Its primary application lies in the modulation of T-cell activity, making it a candidate for treating autoimmune and inflammatory diseases. By blocking the interaction between OX40L and its receptor OX40, oxelumab can suppress excessive immune responses that contribute to conditions such as asthma, lupus, and other chronic inflammatory disorders. It has been investigated in clinical trials for its potential to reduce disease activity and improve patient outcomes, particularly in cases where conventional therapies are ineffective. Additionally, due to its role in immune co-stimulation, oxelumab is being explored in the context of transplant rejection and allergic diseases, where dampening T-cell activation is beneficial.